Literature DB >> 2954497

Safety and efficacy of loratadine (Sch-29851): a new non-sedating antihistamine in seasonal allergic rhinitis.

R J Dockhorn, A Bergner, J T Connell, C J Falliers, S V Grabiec, J M Weiler, M K Shellenberger.   

Abstract

Loratadine, a new antihistamine in the non-sedating class, was evaluated for efficacy and safety in treatment of allergic rhinitis in a multicentered study. Loratadine was found to be both safe and efficacious. When administered to patients with seasonal allergic rhinitis, a single daily oral dose of 10 mg is comparable in efficacy to clemastine, 1 mg, given twice daily. The incidence of sedation with loratadine is comparable to placebo and significantly lower than with clemastine. The incidence of anticholinergic side effects with loratadine is low and in this study was comparable to placebo and clemastine.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2954497

Source DB:  PubMed          Journal:  Ann Allergy        ISSN: 0003-4738


  10 in total

Review 1.  Economic outcomes for the treatment of allergic rhinitis.

Authors:  C M Kozma; M K Sadik; M L Watrous
Journal:  Pharmacoeconomics       Date:  1996-07       Impact factor: 4.981

Review 2.  Hay fever in adolescents and adults.

Authors:  Aziz Sheikh; Sukhmeet Singh Panesar; Sarah Salvilla; Sangeeta Dhami
Journal:  BMJ Clin Evid       Date:  2009-11-18

Review 3.  Optimum pharmacological management of chronic rhinitis.

Authors:  F E Simons; K J Simons
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

Review 4.  Comparative tolerability of second generation antihistamines.

Authors:  F Horak; U P Stübner
Journal:  Drug Saf       Date:  1999-05       Impact factor: 5.606

5.  Loratadine-pseudoephedrine in children with allergic rhinitis, a controlled double-blind trial.

Authors:  H A Serra; O Alves; L F Rizzo; F M Devoto; H Ascierto
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

Review 6.  Impact of allergic rhinitis treatment on quality of life.

Authors:  A Tripathi; R Patterson
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 7.  Drug treatment of allergic conjunctivitis. A review of the evidence.

Authors:  G Ciprandi; S Buscaglia; P M Cerqueti; G W Canonica
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

8.  Cost-benefit analysis of first-generation antihistamines in the treatment of allergic rhinitis.

Authors:  Patrick W Sullivan; Sheryl L Follin; Michael B Nichol
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 9.  Loratadine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  S P Clissold; E M Sorkin; K L Goa
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

Review 10.  Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders.

Authors:  M Haria; A Fitton; D H Peters
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.